Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) ESTRADOT 50 micrograms/24 hours estradiol transdermal patches (Spain)
Section 19A approved medicine
(Approval lapsed) ESTRADOT 50 micrograms/24 hours estradiol transdermal patches (Spain)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Expired
Medicines in short supply/unavailable
ESTRADOT 50 estradiol 50 microgram transdermal drug delivery system sachet - ARTG 338058
Indication(s)
Short term treatment of symptoms of estrogen deficiency due to the menopause, whether natural or surgically induced.
In women with an intact uterus, estrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.
Images
